Connect Sign InMolecular Testing in Prostate Carcinoma
In line with all areas of molecular oncology, molecular testing has also expanded into the area of prostate carcinoma, providing insight into pathobiology of these tumors as well as significantly aiding in identifying diagnostic, prognostic and predictive biomarkers. Most recent guidelines from professional societies now include recommendations for relevant molecular testing in prostate carcinomas to complement the clinical practice. In this presentation, we will discuss relevant established and emerging standard of care molecular biomarkers in prostate carcinoma and the role pathologists can play in identifying clinically relevant molecular biomarkers.
Dr. Deepika Sirohi is a former medical director of molecular oncology at ARUP Laboratories and a former assistant professor at the University of Utah School of Medicine. Dr. Sirohi received her medical degree from the Armed Forces Medical College and then completed a residency in anatomic and clinical pathology at the University of Texas Health Science Center. She completed a genitourinary pathology fellowship at the Cedar-Sinai Medical Center and a molecular genetic pathology fellowship at the University of California. Dr. Sirohi is board certified in anatomic and clinical pathology and molecular genetic pathology. Her research interests include genomic alteration in urologic malignancies, viral oncogenesis, and applications of next generation sequencing to solid tumors.
